Table 4.
Differences in prescribed treatments between the groups stratified by bacilloscopic index.
| Bacilloscopic Index |
||||
|---|---|---|---|---|
| Variable | ≥ 2 (n = 21) | < 2 (n = 35) | Total | p-value |
| Previous treatment | 11 (52.38%) | 15 (42.86%) | 25 (44.64%) | 0.678 |
| Alternative treatment⁎ | 11 (52.38%) | 16 (45.71%) | 27 (48.21%) | 0.136 |
| ROM | 2 (9.52%) | 0 | 2 (3.57%) | |
| WHO MB-MDT | 8 (38.10%) | 19 (54.29%) | 27 (48.21%) | |
| Rifampicin | 20 (95.24%) | 34 (97.14%) | 54 (96.43%) | 1 |
| Dapsone | 14 (66.67%) | 25 (71.43%) | 39 (69.64%) | 0.940 |
| Clofazimine | 21 (100%) | 34 (97.14%) | 55 (98.21%) | 1 |
| Ofloxacin | 12 (57.14%) | 16(45.71%) | 38 (67.86%) | 0.581 |
| Minocycline | 7 (33.33%) | 6 (17.14%) | 13 (23,21%) | 0.288 |
| Moxifloxacin | 2 (9.52%) | 6 (17.14%) | 8 (14.29%) | 0.696 |
ROM,monthly rifampicin + daily ofloxacin and minocycline; WHO MB-MDT, World Health Organization Multibacillary Multidrug Therapy.
⁎
Any treatment different from regular World Health Organization Multidrug Therapy.